{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:12:05Z","timestamp":1791976325227,"version":"4.4.0"},"reference-count":20,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2013,9,13]],"date-time":"2013-09-13T00:00:00Z","timestamp":1379030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["HIP International"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Although prophylactic tranexamic acid (TXA) is a safe, low-cost option to reduce bleeding in patients undergoing total hip replacement (THR), its optimal dose and duration is unknown. We compared the safety and effectiveness of TXA given as either a single injection or continuous infusion in THR patients, hypothesising that a second TXA dose would not offer any clinical advantages over the single injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>One hundred and sixty-four patients undergoing unilateral THR were randomised. Exclusion criteria were history of thromboembolic events (TE), epilepsy, thrombophilia, and severe chronic renal failure. Patients received either a single dose of 30 mg\/kg TXA on induction of surgery (one shot [OS] group), or a loading dose of 10 mg\/kg TXA followed two hours later by a continuous infusion of 2 mg\/kg per hour for 20 hours (one day [OD] group). The primary outcome was blood loss (BL) calculated from haematocrit levels. Secondary outcomes were mortality and TE events within 90 days postoperatively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All patients completed treatment, with none lost to follow-up. Mean BL was 1107 \u00b1 508 ml in Group OS and 1047 \u00b1 442 ml in Group OD (p = 0.43). No patients were transfused prior to Day 10 postoperatively. At final follow-up, no patients had died, and there were no occurrences of major TE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The 30 mg\/kg TXA single shot was as safe as continuous infusion. As it is also less cumbersome, we recommend it as part of routine care in THR patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5301\/hipint.5000090","type":"journal-article","created":{"date-parts":[[2014,4,27]],"date-time":"2014-04-27T08:19:52Z","timestamp":1398586792000},"page":"63-68","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":42,"title":["Single tranexamic acid dose to reduce perioperative morbidity in primary total hip replacement: a randomised clinical trial"],"prefix":"10.1177","volume":"24","author":[{"suffix":"MD","given":"Herv\u00e9","family":"Hourlier","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Polyclinique de la Thi\u00e9rache, Wignehies - France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fennema","sequence":"additional","affiliation":[{"name":"AMR Advanced Medical Research, M\u00e4nnedorf - Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,9,13]]},"reference":[{"key":"bibr1-hipint.5000090","doi-asserted-by":"publisher","DOI":"10.1016\/j.atc.2004.07.004"},{"key":"bibr2-hipint.5000090","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606273342601"},{"key":"bibr3-hipint.5000090","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200211000-00011"},{"key":"bibr4-hipint.5000090","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60835-5"},{"key":"bibr5-hipint.5000090","doi-asserted-by":"publisher","DOI":"10.1080\/00016470510030751"},{"key":"bibr6-hipint.5000090","doi-asserted-by":"publisher","DOI":"10.5435\/00124635-201003000-00002"},{"key":"bibr7-hipint.5000090","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.93B1.24984"},{"key":"bibr8-hipint.5000090","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3054"},{"key":"bibr9-hipint.5000090","first-page":"CD001886.","author":"Henry DA","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr10-hipint.5000090","doi-asserted-by":"publisher","DOI":"10.1080\/000164700317411834"},{"key":"bibr11-hipint.5000090","doi-asserted-by":"publisher","DOI":"10.1080\/00015458.2007.11680081"},{"key":"bibr12-hipint.5000090","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200611000-00026"},{"key":"bibr13-hipint.5000090","unstructured":"HourlierH FennemaP LineB A novel blood-saving plan for less-invasive primary total hip replacement. Orthopedics 20083112 Suppl 2 pii: orthosupersite.com\/view.asp?rID=37188."},{"key":"bibr14-hipint.5000090","first-page":"61","volume":"88","author":"Hourlier H","year":"2006","journal-title":"J Bone Joint Surg Br"},{"key":"bibr15-hipint.5000090","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198303000-00016"},{"key":"bibr16-hipint.5000090","unstructured":"GilcherRO BelcherAJ Predeposit programs. In: SanderG SilvergleidAJ eds. Autologous transfusion. Arlington, VA American Association of Blood Banks 19831"},{"key":"bibr17-hipint.5000090","first-page":"84","volume-title":"Sponsor: Pfizer Australia Pty Ltd","year":"2010"},{"key":"bibr18-hipint.5000090","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2005.09.009"},{"key":"bibr19-hipint.5000090","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2008.09.015"},{"key":"bibr20-hipint.5000090","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-012-2488-z"}],"container-title":["HIP International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.5301\/hipint.5000090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.5301\/hipint.5000090","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.5301\/hipint.5000090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:17:38Z","timestamp":1777450658000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.5301\/hipint.5000090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,13]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.5301\/hipint.5000090"],"URL":"https:\/\/doi.org\/10.5301\/hipint.5000090","relation":{},"ISSN":["1120-7000","1724-6067"],"issn-type":[{"value":"1120-7000","type":"print"},{"value":"1724-6067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,13]]}}}